<DOC>
	<DOCNO>NCT00387582</DOCNO>
	<brief_summary>This study evaluate clinical efficacy intra-vitreal injection Ranibizumab ( Lucentis ) treatment Diabetic Macular Edema compare grid/focal laser .</brief_summary>
	<brief_title>Efficacy Study Lucentis Treatment Diabetic Macular Edema</brief_title>
	<detailed_description>Diabetic macular edema ( DME ) result abnormal leakage macromolecule extracellular space microaneurysms incompetent blood vessel wall due small vessel damage high blood glucose level . Oncotic force allow water extracellular space . Abnormalities retinal pigment epithelium ( RPE ) may reduce normal outflow fluid retina underlie choriocapillaris via pump mechanism ( Ferris et al . 1984 ) . This lead retinal edema macula accompany loss vision . There evidence suggest vascular endothelial growth factor ( VEGF ) play part vessel wall permeability subsequent retinal edema ( Aiello et al . 1997 ) . Studies demonstrate tight junction vessel wall show regulated VEGF VEGF increase vascular permeability ( Anticliff et al . 1999 ) . The healthy human retina contain little VEGF . Hypoxia , component diabetic retinopathy , cause upregulation VEGF retina ( Vinores et al . 1997 ) . Binding VEGF antibody specific VEGF may inhibit resultant edema thus prevent possibly reverse loss vision . Diabetic retinopathy lead cause blindness people age 20-74 year , account 8 % case legal blindness 12 % newly blind ( Klein 1995 ) . A common complication form diabetes mellitus , diabetic retinopathy present 2.5 % U.S. population , 5.3 million people age 18 older ( Prevent Blindness American 2002 ) . Three form retinopathy commonly recognize association form diabetes mellitus : 1 ) non-proliferative diabetic retinopathy ( NPDR ) , 2 ) proliferative diabetic retinopathy ( PDR ) , 3 ) diabetic macular edema ( DME ) . NPDR characterize ophthalmoscopically visable abnormality include microaneurysms , intraretinal hemorrhage , exudate , retina nerve fiber layer infarct ( cotton-wool spot ) , , severe case , venous bead intraretinal microvascular abnormality ( IRMA ) . Over time , NPDR may progress severe PDR , hallmark neovascularization surface retina , optic disc , iris , angle structure front eye . PDR associate high risk visual morbidity arise vitreous hemorrhage , traction retinal detachment , neovascular glaucoma ( Diabetic Retinopathy Research Group 1979 ) . DME , third form diabetic retinopathy , characterize swell central part retina mediate high-resolution vision . DME frequently coexist superimpose upon NPDR PDR . When area swell locate 1 disc diameter ( approximately 1500 mm ) away center fovea , swell constitutes low threat visual acuity regard non-clinically significant macular edema ( Early Treatment Diabetic Retinopathy Study [ ETDRS ] Research Group 1985 ) . Vision deteriorate DME involve foveal center . DME either directly involve fovea high risk refer Clinically Significant Macular Edema ( CSME ) ( ETDRS Research Group 1985 ) . When center fovea involve CSME , DME refer CSME center involvement ( CSME-CI ) , oppose CSME without center involvement ( ETDRS Research Group 1987 ) . The natural history untreated CSME-CI particularly poor . The ETDRS demonstrate 3-year period , 33 % subject CSME-CI lose &gt; 15 letter visual acuity standardize ETDRS Visual Acuity Chart ( Ferris et al . 1982 ) compare 23 % CSME subject without center involvement ( ETDRS Research Group 1987 ) . Such degree visual acuity change equivalent double visual angle great . The ETDRS discriminate subtypes diabetes mellitus . Although laser photocoagulation CSME-CI show reduce proportion subject lose &gt; 15 letter 33 % 13 % 3 year , 13 % subject nevertheless continue double visual angle worse . Moreover , subject CSME initially without center involvement , 3 year , 12 % lose &gt; 15 letter despite laser treatment , presumably edema eventually involve center fovea ( i.e. , subject convert CSME-CI ) . Thus , laser effective tool treatment CSME , considerable unmet clinical need CSME-CI . This study design compare effectiveness intra-vitreal Ranibizumab current standard care .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Subjects eligible follow criterion meet : Clinically significant diabetic macular edema ( CSME ) clinically significant diabetic macular edema center involvement ( CSMECI ) define ETDRS Trial ( ETDRS Research Group 1987 1991 ) Retinal thicken within 500 mm center fovea Hard exudate within 500 mm center fovea ( associate adjacent retinal thickening , may outside 500um limit ) An area macular edema great 1 disc area within 1 disc diameter center macula Ability provide write informed consent comply study assessment full duration study Age &gt; 21 year Visual acuity &lt; 20/320 definite retinal thickening due diabetic macular edema base clinical exam Retinal thickness OCT measure 250 micron central subfield 350 micron noncentral subfield Media clarity pupillary dilatation , patient cooperation , adequate fundus photograph OCT obtainable No ocular condition could cause macular edema present Subjects meet follow criterion exclude study : Other cause macular edema present Intraocular pressure exceed 25 mm Hg Prior enrollment study Any condition investigator believe would pose significant hazard subject investigational therapy initiate Participation another simultaneous medical investigation trial previous trial Lucentis Avastin Premenopausal woman use adequate contraception The following consider effective mean contraception : surgical sterilization , use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , IUD , contraceptive hormone implant patch Pregnancy lactation ( evidence Early Pregnancy Test ( EPT ) counter test ) Current treatment systemic infection Evidence significant uncontrolled concomitant diseases cardiovascular disease , nervous system , pulmonary , renal , hepatic , endocrine , gastrointestinal disorder History recurrent significant infection bacterial infection Any concurrent intraocular condition study eye ( e.g. , cataract diabetic retinopathy ) , opinion investigator , could either Require medical surgical intervention 12month study period prevent treat visual loss might result condition , If allow progress untreated , could likely contribute loss least 2 Snellen equivalent line BCVA 12month study period Active intraocular inflammation ( grade trace ) study eye Current vitreous hemorrhage study eye History rhegmatogenous retinal detachment macular hole ( Stage 3 4 ) study eye History idiopathic autoimmuneassociated uveitis either eye Active infectious conjunctivitis , keratitis , scleritis , endophthalmitis either eye Concurrent ocular disease associate choroidal neovascularization include limit presumed ocular Histoplasmosis , high myopia , macular degeneration Prior/Concomitant Treatment Patient panretinal photocoagulation treatment within 4 month Grid/focal laser within 2 month randomization Subtenon steroid study eye within 6 month Treatment systemic steroid currently within last 4 week IVTA within 3 month Previous participation study investigational drug within 30 day precede Day 0 ( exclude vitamin mineral ) Prior participation Genentech ranibizumab clinical trial Previous treatment intravitreally ( either eye ) intravenously administer Avastin ( bevacizumab ) Concurrent use systemic antiVEGF agent Previous use Macugen study eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Macular Edema</keyword>
	<keyword>Diabetic Retinopathy</keyword>
	<keyword>Lucentis</keyword>
	<keyword>Ranibizumab</keyword>
</DOC>